Design, Synthesis, and Biological Activities Evaluation of Type I FLT3 Inhibitors for the Treatment of Acute Myeloid Leukemia
Related Experiment Video
Updated: Jun 7, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
Jin Yang1, Yan Zhang1, Yue-Chu Li1
1National and Local Collaborative Engineering Center of Chinese Medicinal Resources Industrialization and Formulae Innovative Medicine, Nanjing University of Chinese Medicine, Nanjing, Jiangsu, China.
Abstract:
The abnormal overexpression of FLT3 kinase is intimately associated with pathogenesis of acute myeloid leukemia (AML), positioning FLT3 inhibitors as pivotal therapeutic agents. Despite the availability of three FDA-approved FLT3 inhibitors, their clinical utility is hampered by resistance stemming from tyrosine kinase domain (TKD) mutations. Through an integrative analysis of case studies, we identified a potential advantage of type I FLT3 inhibitors in overcoming TKD mutation-induced resistance. Structure-activity relationships (SAR) analysis indicated that FW-1 exhibited over 50% inhibition against FLT3 at a concentration of 1 μM and demonstrated potent activity against AML cell lines MV4-11 (IC50 = 2.68 μM) and MOLM-13 (IC50 = 1.03 μM). In our cellular mechanistic studies, FW-1 also effectively induced apoptosis by arresting cell cycle progression in the G0/G1 phase. This study introduces FW-1 as a promising lead for type I FLT3 inhibitor, warranting further optimization.
Insights
A novel type I FLT3 inhibitor, FW-1, shows promise in overcoming resistance in acute myeloid leukemia (AML) caused by tyrosine kinase domain mutations. FW-1 effectively inhibits FLT3 kinase and induces apoptosis in AML cell lines, suggesting its potential as a therapeutic lead.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- FLT3 kinase overexpression is a key driver in acute myeloid leukemia (AML) pathogenesis.
- Existing FLT3 inhibitors face challenges due to resistance mutations in the tyrosine kinase domain (TKD).
Purpose of the Study:
- To identify and characterize novel type I FLT3 inhibitors capable of overcoming TKD mutation-induced resistance.
- To evaluate the preclinical efficacy of a newly identified compound, FW-1, in AML models.
Main Methods:
- Integrative analysis of case studies to identify therapeutic advantages.
- Structure-activity relationship (SAR) analysis of potential FLT3 inhibitors.
- In vitro assessment of FW-1's inhibitory activity against FLT3 kinase and AML cell lines (MV4-11, MOLM-13).
- Cellular mechanistic studies to investigate apoptosis induction and cell cycle arrest.
Main Results:
- FW-1 demonstrated over 50% FLT3 inhibition at 1 μM.
- Potent activity was observed against MV4-11 (IC50 = 2.68 μM) and MOLM-13 (IC50 = 1.03 μM) AML cell lines.
- FW-1 induced apoptosis and G0/G1 cell cycle arrest in cellular mechanistic studies.
Conclusions:
- FW-1 represents a promising lead compound for a new class of type I FLT3 inhibitors.
- Further optimization of FW-1 is warranted for potential AML therapeutic development, particularly for overcoming resistance mutations.
Related Concept Videos
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...